Drugs / PBP1502
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05108259 | Mar 2022 → Feb 2026 overdue | — | Prestige Biopharma Limited | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PBP1502 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05108259 ↗ |
| Route | Subcutaneous | “40 mg/0.4 mL single SC injection via PFS” NCT05108259 ↗ |